表紙
市場調査レポート

経皮的疼痛管理:製品・市場・予測・機会

Transdermal Pain Management to 2020- Products, Markets, Opportunities and Forecasts

発行 Greystone Research Associates 商品コード 138804
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
経皮的疼痛管理:製品・市場・予測・機会 Transdermal Pain Management to 2020- Products, Markets, Opportunities and Forecasts
出版日: 2014年12月01日 ページ情報: 英文
概要

当レポートは、経皮鎮痛剤の経済的な側面、技術、治療可能な条件、商業的な可能性などを詳細に分析したもので、市場の成長促進要因や今後の見通しに加え、主要企業のプロファイルも盛り込んでお届けいたします。

エグゼクティブサマリー

調査範囲・定義

疼痛管理市場のビジネスチャンス

  • 疼痛管理指針の進化
  • 疼痛管理治療の地域的な要因
  • 需要促進要因
  • 競合状況
  • 成長阻害要因

経皮ドラッグデリバリーの力学

  • 経皮鎮痛パッチ
    • 鎮痛パッチの技術とアーキテクチャー
    • 経皮パッチの生産とパッケージング
    • パッチの経済的な側面
    • パッシブ方式とアクティブ方式のデリバリーシステム
  • 経皮鎮痛ジェル
    • 経皮処方
    • 知的財産と独自技術
    • 局所ジェルの制約

経皮鎮痛剤の評価と市場の見通し

  • FDAが認可した経皮鎮痛剤
    • 麻酔薬
    • 非ステロイド系抗炎症剤
    • 局所麻酔
  • FDAが認可していない経皮鎮痛剤
    • 麻酔薬
    • 非ステロイド系抗炎症剤
    • 局所麻酔
  • 開発段階にある経皮鎮痛剤
    • 麻酔薬
    • 非ステロイド系抗炎症剤
    • 他の薬剤クラス

経皮的疼痛管理市場の要因

  • 各国の規制
  • 品質と信頼性
  • 適応症処方ガイドラインとFDA認可外の処方
  • マネージドケアとペイヤーイニシアティブ
  • 皮膚パッチの収益モデル

市場予測

  • 地域別の予測
  • 薬剤クラス別の予測
  • デリバリー形態別の予測
  • 市場シェアデータ

企業プロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: TPX602R

‘Transdermal Pain Management to 2020: Products, Markets, Opportunities and Forecasts’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the pain management drug sector.

The study is designed to provide drug company decision makers, pain product managers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, treatable conditions, and commercial opportunities for transdermal pain management. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Drug Products and Candidates for a Growing Clinical Need

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to transdermal formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, transdermal delivery addresses a key healthcare issue - one that is particularly problematic in aging populations and developing economies. Currently approved transdermal pain products include narcotics, NSAIDs, and topical anesthetics. These patches and gels will encounter competition from development-stage transdermal formulations for a number of pain medications presently being marketed in oral or parenteral form. Several of these development programs involve international partnerships designed to take advantage of perceived opportunities in regional markets.

What You Will Learn

  • What drugs indicated for managing pain are supplied as transdermal formulations, what are the formulation and product specifics, and who markets them
  • Who are the branded transdermal pain management product suppliers, their business models, and their capabilities
  • What are the major factors driving transdermal pain product demand
  • How important are drug developer-formulator-device manufacturer relationships and what are the key alliances in the industry
  • What are the essential design factors, material selection issues, technologies and market development issues for transdermal pain management products
  • What are the competing pain management product segments and what is their market share
  • What are the significant economic, technology, and regulatory factors affecting the market for transdermal pain management

Table of Contents

Executive Summary

  • Scope and Definitions
  • The Current Pain Management Picture
  • Unmet Needs in Pain Management
  • The Opportunity for Transdermal Delivery of Pain Drugs

The Pain Management Market Opportunity

  • Evolution in Pain Management Guidelines
  • Regional Factors in Pain Management Practice
  • Pain Management Demand Drivers
  • Competitive Landscape
  • Factors Limiting Growth

Transdermal Drug Delivery Dynamics

  • Transdermal Pain Management Patches
    • Pain Patch Technology & Architectures
    • Transdermal Patch Manufacturing and Packaging
    • Patch Economics
    • Passive vs Active Delivery Systems
  • Transdermal Pain Management Gels
    • Transdermal Formulations
    • IP and Proprietary Technology
    • Limitations of Topical Gels

Transdermal Pain Management Product Assessments and Market Prospects

  • FDA Approved Transdermal Pain Management Products
    • Narcotic
    • NSAIDs
    • Local Anesthetic
  • Non-FDA Approved Commercial Transdermal Pain Management Products
    • Narcotic
    • NSAIDs
    • Local Anesthetic
  • Development-Stage Transdermal Pain Management Products
    • Narcotic
    • NSAID
    • Other Drug Classes

Transdermal Pain Management Market Factors

  • Regional Regulations
  • Quality and Reliability
  • Indications Prescribing Guidelines and Off-Label Prescribing
  • Managed Care and Payor Initiatives
  • Skin Patch Revenue Models

Market Forecasts

  • Forecasts by Region
  • Forecasts by Drug Class
  • Forecasts by Delivery Form Factor
  • Market Share Data

Company Profiles

Back to Top